1. An Evaluation of a Low-Density DNA Microarray Using Cytochrome P450 Inducers
- Author
-
José Remacle, Bindi Sohal, Georgina Meneses-Lorente, Andrew Pike, Vincent Bertholet, Paul Scott-Stevens, Francoise De Longueville, Timothy P. Bonnert, Sofia Dos Santos-Mendes, Stephanie Evrard, and Andrew D. Jack
- Subjects
Genetic Markers ,Miconazole ,Microarray ,Drug Evaluation, Preclinical ,Administration, Oral ,Gene Expression ,Biology ,Toxicology ,Dexamethasone ,Troleandomycin ,Rats, Sprague-Dawley ,Cytochrome P-450 Enzyme System ,Gene expression ,medicine ,Animals ,Clotrimazole ,Gene ,Oligonucleotide Array Sequence Analysis ,Messenger RNA ,Drug discovery ,Gene Expression Profiling ,Cytochrome P450 ,General Medicine ,Molecular biology ,Rats ,Liver ,Clofenapate ,biology.protein ,Hybridization, Genetic ,Female ,DNA microarray ,Forecasting ,medicine.drug - Abstract
The aim of this study was to validate a low-density DNA microarray "Rat HepatoChip", which contains 59 genes from a range of potential toxic markers and drug metabolism-related genes. Liver mRNA was isolated from rats dosed with six different chemicals, dexamethasone, troleandomycin, miconazole, clotrimazole, and methylclofanapate, which are all known to induce different cytochrome P450 genes, and isoniazid, which does not cause histopathological changes. Replicate microarrays were used to measure the variability in the chips and in the process. The average variability in signal between different chips observed in triplicate experiments was 33% ranging from 21 to 39% depending on genes. We also demonstrated a strong correlation between the liver histopathology and the gene expression profiles indicating that the gene expression profile reflects histopathological changes. These results suggest that the Rat HepatoChip microarray may provide a fast and effective tool for assessing the toxicity profile of developmental drug candidates during the drug discovery process.
- Published
- 2003
- Full Text
- View/download PDF